First RNA-based cat vaccine range launches in Europe
MSD Animal Health has launched Nobivac NXT, a range of feline vaccines that includes the first veterinary vaccine to use self-amplifying RNA technology approved in the European Union.
The range was unveiled ahead of the WSAVA World Congress in Warsaw. It follows EU marketing authorisation for its combination vaccine, Nobivac NXT HCPChFeLV. According to MSD, the range consists of six vaccines. They use a low-volume dose and provide immunity from around one week after vaccination.
Five key pathogens covered
The range targets feline herpesvirus type 1 (FHV), feline calicivirus (FCV), feline panleucopenia virus (FPLV), Chlamydia felis and feline leukaemia virus (FeLV). The combination product covers all five in a single 0.5ml subcutaneous dose.
Four of the five components are live attenuated strains. The FeLV component works differently. It uses self-amplifying RNA carried in a replication-deficient particle, which prompts the cat’s cells to briefly produce a FeLV protein and so trigger an immune response.
MSD says the vaccines provide up to three years of immunity against FHV, FCV, FPLV and FeLV, and one year against Chlamydia felis.
The regulatory review drew on 15 laboratory studies and a field study involving 142 cats. The most common side effects were short-lived swelling at the injection site and raised temperature. The vaccine is for use in healthy cats only.
UK availability
As an EU-authorised product, the range can be used in Northern Ireland. It is not yet authorised for use in Great Britain.
Vets and owners out of step
MSD also published results from a survey it commissioned of 1,330 vets across 14 countries, including the UK, and more than 5,000 cat owners.
Almost seven in 10 vets (69%) ranked vaccination among the three most important factors in keeping cats healthy. Only 16% of owners did the same. Of the owners who had chosen not to vaccinate, 27% said this was because their cat was healthy or lived indoors.
The survey also pointed to a communication gap. Fifty-eight per cent of owners said their vet was their main source of vaccine information, but only 23% of vets said they gave owners educational material on the subject.
The company described the range as the biggest advance in feline vaccination for two decades. It said it hopes the launch will encourage clearer conversations between practices and owners. Pedro Silva, senior vice-president for MSD’s EURAM region, presented vaccination as a central part of preventive care.
Nathaniel Whitley, a vet and RCVS fellow, said the range could help tackle vaccine hesitancy. He noted that vets are well placed to assess each cat’s individual risk. He added that a range supporting tailored protocols gives vets more flexibility when making recommendations.
MSD estimates that more than three million doses of its RNA vaccines have been sold or administered in North America over the past two years.



